Oncolytics Biotech (TSE:ONC) Stock Price Down 3.4% – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC) fell 3.4% during mid-day trading on Wednesday . The company traded as low as C$1.10 and last traded at C$1.13. 103,662 shares traded hands during trading, an increase of 2% from the average session volume of 101,767 shares. The stock had previously closed at C$1.17.

Analysts Set New Price Targets

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The stock has a market cap of C$93.00 million, a PE ratio of -3.18 and a beta of 1.35. The business’s 50-day moving average price is C$1.31 and its 200-day moving average price is C$1.39.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.